Herbal Supplement ‘Kratom’ Used as Pain-Relieving Alternative, Receives Further Research Funding
guvo59 / Pixabay

Herbal Supplement ‘Kratom’ Used as Pain-Relieving Alternative, Receives Further Research Funding

Kratom, an herbal supplement of the caffeine family used to ward off pain for chronic pain conditions, has received large grants for further research. While many consumers claim the supplement…

Continue Reading Herbal Supplement ‘Kratom’ Used as Pain-Relieving Alternative, Receives Further Research Funding
Recent Study Finds Better Than Expected Safety Data for TNF Inhibitors in Ankylosing Spondylitis
skeeze / Pixabay

Recent Study Finds Better Than Expected Safety Data for TNF Inhibitors in Ankylosing Spondylitis

According to a story from Ankylosing Spondylitis News, a recent study has found that the class of drugs known as tumor necrosis factor (TNF) inhibitors may actually be safer for…

Continue Reading Recent Study Finds Better Than Expected Safety Data for TNF Inhibitors in Ankylosing Spondylitis
Minovia Kicks Off Phase I/II Trial of Experimental Pearson Syndrome Treatment
source: pixabay.com

Minovia Kicks Off Phase I/II Trial of Experimental Pearson Syndrome Treatment

According to a publication from Business Wire, the Israeli biotechnology company Minovia Therapeutics recently finished dosing the first participant in a phase I/II clinical study of the Company's experimental mitochondrial…

Continue Reading Minovia Kicks Off Phase I/II Trial of Experimental Pearson Syndrome Treatment
Study Identifies Broader Range of Clinical Presentation for Mitochondrial Disease
geralt / Pixabay

Study Identifies Broader Range of Clinical Presentation for Mitochondrial Disease

According to a story from Wellcome Center Mitochondrial Research, a multi-center collaborative study that involved researchers from different sites around the UK has resulted in an improved understanding of the…

Continue Reading Study Identifies Broader Range of Clinical Presentation for Mitochondrial Disease

FDA Approves Soliris for Treatment of Neuromyelitis Optica Spectrum Disorder

According to a publication at Markets Insider, the Food and Drug Administration (FDA) recently approved Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder. The approval marks the first…

Continue Reading FDA Approves Soliris for Treatment of Neuromyelitis Optica Spectrum Disorder
Close Menu